Second Quarter Ended June 30, 2026
Filed Aug 3, 2026Alexandria reported selected balance-sheet, capital-source, and operating highlights for the second quarter ended June 30, 2026, but the provided filing excerpt does not include the earnings press release financial-results pages.
The excerpt presents significant liquidity, long debt duration, and progress on dispositions, while also showing a BBB+ Negative credit-rating outlook and a stated need to execute additional capital sources to support leverage targets.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Alexandria’s Megacampus™ platform as a percentage of annual rental revenueother | 80% | – | – |
| Significant liquidityother | $3.6B | – | – |
| Percentage of fixed-rate debt since 2022other | 95.7% | – | – |
| Remaining debt termother | 9.7 years | – | – |
| Debt interest rateother | 4.08% | – | – |
| Completed dispositions as of August 3, 2026other | $170.4 million | – | – |
| Share of pending dispositions and sales of partial interests subject to non-refundable deposits, signed letters of intent, or purchase and sale agreement negotiations as of August 3, 2026other | $1.16 billion | – | – |
4Q26 annualized guidance outlook
- NoteNet debt and preferred stock to adjusted EBITDA: 5.6x to 6.2x
- NoteFixed-charge coverage ratio: 3.6x to 4.1x
- Note2026 sources of capital: $2.9B guidance midpoint
What drove it
- Alexandria’s Megacampus™ platform represents 80% of annual rental revenue.
- A new 426,927 RSF facility for Bristol Myers Squibb was delivered in June 2026 under a 15-year lease.
- The company stated it is focusing on steadily improving occupancy and increasing NOI through leasing to all sectors of its tenant base.
- The company stated it is reducing capital spend and funding needs while prioritizing capital necessary to lease space.
- The company stated it does not anticipate the issuance of any common equity during the year ending December 31, 2026.
Concerns
- The S&P credit rating was BBB+ Negative.
- The company stated that dispositions, sales of partial interests, and other capital sources are intended to support achievement of leverage-ratio targets.
- The provided excerpt does not include the financial-results pages needed to assess reported revenue, earnings, FFO, cash flow, occupancy, leasing activity, or same-property performance.
What to watch
- Execution against annualized 4Q26 net debt and preferred stock to adjusted EBITDA guidance of 5.6x to 6.2x.
- Execution against annualized 4Q26 fixed-charge coverage ratio guidance of 3.6x to 4.1x.
- Completion of pending dispositions and sales of partial interests aggregating $1.16 billion as of August 3, 2026.
- Occupancy and NOI improvement from leasing activity.
- Progress toward the $2.9B guidance midpoint for 2026 sources of capital.
Balance sheet and cash flow
- Significant liquidity: $3.6B
- Percentage of fixed-rate debt since 2022: 95.7%
- Remaining debt term: 9.7 years
- Debt interest rate: 4.08%
- Credit ratings: BBB+ Negative; Baa2 Stable
- Completed dispositions as of August 3, 2026 aggregated $170.4 million.
- Our share of pending dispositions and sales of partial interests subject to non-refundable deposits, signed letters of intent, or purchase and sale agreement negotiations aggregated $1.16 billion.
- Pro forma for the amended and restated unsecured senior line of credit, weighted-average remaining debt term would have been 10.0 years.
Analysis
The provided excerpt does not contain the earnings press release pages with the company’s quarterly income statement, FFO results, revenue, net income, EPS, or cash-flow disclosures. It does identify the reporting period as the second quarter ended June 30, 2026 and provides selected operating and balance-sheet highlights. Consequently, the reported period cannot be evaluated on earnings growth, profitability, or cash-flow performance from the supplied text.
The operating material emphasizes the concentration of Alexandria’s platform in megacampuses, which represented 80% of annual rental revenue as of June 30, 2026. The company also delivered a 426,927 RSF R&D hub for Bristol Myers Squibb in June 2026 under a 15-year lease. Management’s stated operating priorities are to improve occupancy, increase NOI, and lease space across its tenant base, while reducing capital spend and funding needs.
Balance-sheet disclosures in the excerpt show $3.6B of significant liquidity, a 9.7-year remaining debt term, and a 4.08% debt interest rate. The reported percentage of fixed-rate debt since 2022 was 95.7%. The company’s credit ratings were shown as BBB+ Negative and Baa2 Stable, making the negative S&P outlook an important disclosed counterpoint to the liquidity and debt-maturity profile.
Capital sourcing is central to the stated plan. As of August 3, 2026, completed dispositions aggregated $170.4 million, while the company’s share of pending dispositions and sales of partial interests aggregated $1.16 billion. Alexandria stated that it did not anticipate issuing common equity during the year ending December 31, 2026, and presented a $2.9B guidance midpoint for 2026 sources of capital.
The forward balance-sheet targets shown in the excerpt are annualized 4Q26 net debt and preferred stock to adjusted EBITDA of 5.6x to 6.2x and fixed-charge coverage of 3.6x to 4.1x. Investors should focus on execution of pending capital transactions, progress in occupancy and NOI, and delivery against these leverage and coverage targets. No previous outlook was supplied, so no comparison of reported results with prior guidance is available.
Not in the filing
stated, not guessed- Total revenue and revenue comparisons
- Segment revenue and segment comparisons
- GAAP gross margin
- GAAP operating income
- GAAP net income
- GAAP EPS
- Non-GAAP earnings measures, including FFO and FFO per share
- Operating cash flow
- Free cash flow
- Dividend declaration or payment
- Share repurchases
- Cash balance
- Total debt balance
- Quarter-end occupancy
- Leasing activity metrics
- Same-property performance metrics
- Full 2026 guidance ranges and all guidance assumptions
- Prior-period guidance for comparison
- Named executive earnings commentary or attributable executive quotes
- Full financial-results pages, consolidated statements of operations, balance sheets, and FFO reconciliation referenced in the table of contents
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.